Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: serum uric acid test.
- Who it may be relevant to
- Registry conditions: Serum Uric Acid. Basic parameters: 18 years — 85 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer
Overview
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Detailed description
Serum uric acid is a risk factor for gallbladder cancer in men and has a strong effect on pancreatic cancer in women. It has also been shown that elevated intracellular serum uric acid can induce an inflammatory stress response, which may promote its transformation, while elevated extracellular serum uric acidy further stimulate tumor cell proliferation, migration, and survival, and promote the development of highly aggressive cancer. In this study, the changes of serum uric acid before and after surgery was used as a prognostic marker for the survival of pancreatic cancer patients.
Interventions
- Diagnostic test serum uric acid test
Detect the serum uric acid in blood sample
Primary outcome measures
- Overall survival [Time frame: 3-5 years]
Secondary outcome measures (7)
- Recurrence-free survival [Time frame: 3-5 years]
- Cost of hospitalization [Time frame: 3 months]
- Length of hospital stay [Time frame: 3 months]
- Pancreatic fistula [Time frame: 3 months]
- Biliary fistula [Time frame: 3 months]
- Bleeding [Time frame: 3 months]
- Abdominal cavity infection [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- Patients with pathologically confirmed pancreatic cancer (primary)
- Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy）
- The postoperative survival time was at least 6 weeks
Exclusion criteria
- No surgery was performed, or only palliative surgery/ biopsy was performed
- Patients who underwent emergency hemodialysis or plasma exchange after surgery
- History of gout or long-term urate-lowering therapy, such as allopurinol
- Patients are missing follow-up data
- Hydrochlorothiazide and furosemide were used
- Chronic kidney disease
- Oncolytic syndrome
- Hemolytic anemia
- Lead poisoning
- Hyperparathyroidism
- Hypothyroidism
- A tyrosinase inhibitor was used
- Patients with nonpancreatic primary tumors
- Pregnant or postpartum women.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Hepatopancreatobiliary Surgery Institute of Gansu Province — Lanzhou
Publications
- Huang CF, Huang JJ, Mi NN, Lin YY, He QS, Lu YW, Yue P, Bai B, Zhang JD, Zhang C, Cai T, Fu WK, Gao L, Li X, Yuan JQ, Meng WB. Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study. World J Gastroenterol. 2020 Nov 28;26(44):7061-7075. doi: 10.3748/wjg.v26.i44.7061. PMID 33311950
- Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012 Aug 15;1(1):16. doi: 10.1186/2001-1326-1-16. PMID 23369448
Identifiers
NCT: NCT07091526 · SUA-PC